Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scivision BiotechTPE:1786 -1.61%77 EV-to-EBITDA is 10.19 as of Aug. 29, 2026, which is 53% below its 10-year median of 21.82. GuruFocus rates TPE:1786 with a GF Score™ of 77/100 and a GF Value™ of NT$101.38 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 523 Medical Devices & Instruments companies, Scivision Biotech ranks better than 63.86% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Scivision Biotech's enterprise value is NT$3,127.3 Mil.
Scivision Biotech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$306.8 Mil. Therefore, Scivision Biotech's EV-to-EBITDA for today is 10.19.
The historical rank and industry rank for Scivision Biotech's EV-to-EBITDA or its related term are showing as below:
TPE:1786'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -572.92 Med: 21.82 Max: 93.39
Current: 10.19
During the past 13 years, the highest EV-to-EBITDA of Scivision Biotech was 93.39. The lowest was -572.92. And the median was 21.82.
TPE:1786's EV-to-EBITDA is ranked better than 63.86% of 523
companies
in the Medical Devices & Instruments industry
Industry Median: 14.62
vs TPE:1786: 10.19
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Scivision Biotech's PE Ratio (TTM) for today is calculated as:
Scivision Biotech's share price for today is NT$48.80.
Scivision Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$2.360.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Scivision Biotech's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1786 vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Scivision Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scivision Biotech EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Scivision Biotech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Scivision Biotech's EV-to-EBITDA falls into.
Scivision Biotech's current Enterprise Value is NT$3,127.3 Mil.
Scivision Biotech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$306.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scivision Biotech (TPE:1786) has a EV-to-EBITDA of 10.19 as of Aug. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Scivision Biotech. This is 53% below median its historical median of 21.82. According to the industry distribution chart, Scivision Biotech ranks #189 out of 523 companies in the Medical Devices & Instruments industry, placing it in the top 36.1%.
Is Scivision Biotech's EV-to-EBITDA too high?
Scivision Biotech's current EV-to-EBITDA of 10.19 is 53% below median its 10-year median of 21.82. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.62. Scivision Biotech's value of 10.19 is 30.3% below this industry median. Based on the distribution chart, Scivision Biotech ranks #189 out of 523 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Scivision Biotech has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scivision Biotech's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Scivision Biotech ranks #189 out of 523 companies for EV-to-EBITDA. This puts Scivision Biotech in the upper half of its industry. The industry median EV-to-EBITDA is 14.62. Scivision Biotech's value of 10.19 is 30.3% below this benchmark. While the company's 10-year median is 21.82 vs. the industry median of 14.62, Scivision Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.62, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scivision Biotech's current EV-to-EBITDA of 10.19 is 30.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Scivision Biotech. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scivision Biotech's current EV-to-EBITDA is 10.19, which is 53% below median its own 10-year median of 21.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scivision Biotech stock overvalued right now?
Based on GuruFocus' analysis, Scivision Biotech (TPE:1786) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$101.38, compared to a current price of NT$48.80 — trading 51.9% below its estimated fair value. The current EV-to-EBITDA is 10.19, which is 53% below median its 10-year median of 21.82 and 30.3% below the Medical Devices & Instruments industry median of 14.62. Scivision Biotech's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Scivision Biotech (TPE:1786), the current EV-to-EBITDA is 10.19 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scivision Biotech (TPE:1786) Overvalued in 2026?
Based on GuruFocus' analysis, Scivision Biotech stock appears to be undervalued.
The current stock price of NT$48.80 is trading 51.9% below its estimated GF Value™ of NT$101.38.
GuruFocus considers Scivision Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1786:
EV-to-EBITDA: 10.19 (53% below median its 10-year median of 21.82)
GF Value™: NT$101.38 vs. price of NT$48.80 (51.9% below fair value)
Industry Position: 30.3% below the Medical Devices & Instruments median (#189 of 523)
No single metric tells the full story. See the TPE:1786 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scivision Biotech Inc is engaged in the manufacturing and distribution of hyaluronic acid medical supplies in Taiwan. It offers medical devices, including absorbable adhesion barriers, dermal implants, synovial fluid supplements, and intravesical instillation.
77GF Score
Get the complete analysis for TPE:1786
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1786 has been successfully added to your 
